{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:18:01Z","timestamp":1783570681769,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.taap.2016.10.017","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T22:32:18Z","timestamp":1477002738000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Differential modulation of FXR activity by chlorophacinone and ivermectin analogs"],"prefix":"10.1016","volume":"313","author":[{"given":"Chia-Wen","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Hua","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai","family":"Khuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinie","family":"van Beuningen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Houtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2016.10.017_bb0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/tx300463b","article-title":"Robust array-based coregulator binding assay predicting ERalpha-agonist potency and generating binding profiles reflecting ligand structure","volume":"26","author":"Aarts","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2016.10.017_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064721","article-title":"Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH","volume":"8","author":"Bjursell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2016.10.017_bb0015","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1006\/mgme.2000.3106","article-title":"Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids","volume":"71","author":"Bramlett","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.taap.2016.10.017_bb0020","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2016.10.017_bb0025","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.27910","article-title":"Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts","volume":"119","author":"Guan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.taap.2016.10.017_bb0030","doi-asserted-by":"crossref","first-page":"45062","DOI":"10.1074\/jbc.M307145200","article-title":"Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity","volume":"278","author":"Guo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.taap.2016.10.017_bb0035","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.abb.2004.08.030","article-title":"Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR","volume":"433","author":"Handschin","year":"2005","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.taap.2016.10.017_bb0040","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1535-7163.MCT-11-0855","article-title":"Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen","volume":"11","author":"Houtman","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2016.10.017_bb0045","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1038\/srep06437","article-title":"Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor","volume":"4","author":"Hsu","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2016.10.017_bb0050","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1289\/ehp.1002952","article-title":"Chemical genomics profiling of environmental chemical modulation of human nuclear receptors","volume":"119","author":"Huang","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.taap.2016.10.017_bb0055","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1038\/ncomms2924","article-title":"The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism","volume":"4","author":"Jin","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2016.10.017_bb0060","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bbadis.2010.11.011","article-title":"Regulation of FXR transcriptional activity in health and disease: emerging roles of FXR cofactors and post-translational modifications","volume":"1812","author":"Kemper","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.taap.2016.10.017_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.10.017_bb0070","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1074\/mcp.M900209-MCP200","article-title":"Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor","volume":"8","author":"Koppen","year":"2009","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.taap.2016.10.017_bb0075","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2174\/1568026614666141112103516","article-title":"Medicinal chemistry and pharmacological effects of farnesoid X receptor (FXR) antagonists","volume":"14","author":"Lamers","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.taap.2016.10.017_bb0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI68815","article-title":"Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk","volume":"124","author":"Lien","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2016.10.017_bb0085","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1038\/srep10405","article-title":"Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor","volume":"5","author":"Lynch","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2016.10.017_bb0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.108.145409","article-title":"Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development","volume":"328","author":"Maran","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2016.10.017_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030443","article-title":"Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis","volume":"7","author":"Renga","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2016.10.017_bb0100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/dmd.110.035105","article-title":"Identification of clinically used drugs that activate pregnane X receptors","volume":"39","author":"Shukla","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2016.10.017_bb0105","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1126\/science.1072891","article-title":"A natural product that lowers cholesterol as an antagonist ligand for FXR","volume":"296","author":"Urizar","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.taap.2016.10.017_bb0110","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.2337\/db10-0019","article-title":"Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model","volume":"59","author":"Wang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.taap.2016.10.017_bb0115","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2016.10.017_bb0120","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/j.bmc.2013.04.069","article-title":"Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery","volume":"21","author":"Yu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.taap.2016.10.017_bb0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/me.2011-1157","article-title":"Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob\/ob mice","volume":"26","author":"Zhang","year":"2012","journal-title":"Mol. Endocrinol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X1630326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X1630326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T06:29:25Z","timestamp":1536301765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X1630326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":25,"alternative-id":["S0041008X1630326X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2016.10.017","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential modulation of FXR activity by chlorophacinone and ivermectin analogs","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}